The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 29 rounds in the feed, most often at Series A and in Biotech.
The information on these pages is intended solely for the benefit of entrepreneurs seeking venture capital investments.
Venture capitalCambridge, MA, USAfprimecapital.comRounds from 2017-10-02 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B Verified against 1 of 67 sources | $133M | 2026-11-05 | [ PART ] |
Eureka Robotics Robotics technology company | Series A |
| $150M |
| ~ 2026-10-23 |
| [ LEAD ] |
Zenflow Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH). | Series D Verified against 1 of 16 sources | $52M | 2026-10-05 | [ PART ] |
Arboretum LifeSciences A molecular information company | Series A Verified against 4 of 11 sources | $30M | 2026-10-05 | [ LEAD ] |
AblePay Health AblePay Health makes paying out-of-pocket medical expenses easy and convenient for patients and removes providers from the payment process. | Series A Verified against 3 of 9 sources | $20M | ~ 2026-10-05 | [ LEAD ] |
Silicon Data The independent benchmark and verification layer for the compute economy | Series A contradicted[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $30.5M | 2026-08-11 | [ PART ] |
Venice Developer of platform enabling private AI access | Series A Verified against 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $65M | 2026-07-01 | [ PART ] |
R1 Therapeutics A biopharmaceutical company focused on developing therapies for kidney disease | Series A Verified against 1 of 7 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $77.5M | 2026-03-17 | [ LEAD ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |
Tenvie Precision-engineered small molecule therapies for neurological and peripheral diseases targeting patients and caregivers. | Funding round Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-08 | [ LEAD ] |
Albert Invent A chemistry-native AI operating system for R&D | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $22.5M | 2024-12-11 | [ PART ] |
Zenflow Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH). | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $24M | 2024-11-18 | [ PART ] |
AvenCell Therapeutics A privately held clinical-stage company developing CAR-T therapies | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2024-10-22 | [ PART ] |
Xaira Therapeutics Xaira Therapeutics sells AI-driven solutions to accelerate drug discovery and development, targeting biopharmaceutical companies and healthcare providers. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.0B | 2024-04-24 | [ PART ] |
Devoted Health Devoted Health sells Medicare Advantage plans and related healthcare services, primarily targeting seniors seeking health insurance options. | Series D+ Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-12-29 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $90M | 2023-12-07 | [ PART ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $59.8M | 2023-11-15 | [ LEAD ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-09-27 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $23M | 2023-06-21 | [ LEAD ] |
MoEngage Agentic Customer Engagement Platform | Funding round Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2021-12-08 | [ PART ] |
Oviva Group Oviva provides personalized dietary advice and digital tools for individuals seeking to improve their health. | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $80M | ~ 2021-09 | [ PART ] |
Zenflow Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH). | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $24M | 2021-06-02 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35.5M | 2020-04-27 | [ PART ] |
MoEngage Agentic Customer Engagement Platform | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $25M | 2020-02-11 | [ PART ] |
Insilico Medicine AI-powered drug discovery and development tools to pharmaceutical companies and researchers. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $37M | 2019-09-10 | [ PART ] |
Vestwell Workplace Retirement & Savings Platform | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2019-04-02 | [ PART ] |
Devoted Health Devoted Health sells Medicare Advantage plans and related healthcare services, primarily targeting seniors seeking health insurance options. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $300M | 2018-10-16 | [ PART ] |
Vestwell Workplace Retirement & Savings Platform | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $8M | 2017-10-02 | [ LEAD ] |